News Sentiment

DARE sentiment intelligence

Dare Bioscience Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.02 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-3.3% over one week, +0.0% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -3.3% Price reacting lower
Trend fit Trend active 0.0% over four weeks
Fair value -42.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 38
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
GlobeNewswire 9
TradingView 7
Market source 6
simplywall.st 3
TradingKey 2
富途牛牛 1
Moomoo 1

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 19
Balance sheet 2
Regulatory and legal 2
Guidance 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
富途牛牛 Direct company coverage

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Daré Bioscience will host a conference call and live webcast on Monday, March 31, 2025, at 4:30 p.m. Eastern Time. The call will cover the company's financial results for the year ended December 31, 2024, and provide a general company update. Interested parties can access the cal

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 15:42
Source
富途牛牛
Stock Titan Direct company coverage

[8-K] Dare Bioscience, Inc. Reports Material Event

Dare Bioscience, Inc. (DARE) has filed an 8-K report announcing the furnishing of a new corporate presentation dated July 13, 2026. This presentation is being used in meetings with securities market participants and will be available in the Investors section of the company's webs

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 15:42
Source
Stock Titan
GlobeNewswire Direct company coverage

Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event

Sabrina Martucci Johnson, CEO of Daré Bioscience (NASDAQ: DARE), will participate in a Virtual Investor Closing Bell event on July 14, 2026, at 4:00 PM ET. She will provide a corporate overview, highlighting the recent launch of FloraSync LF5™, the company's commercial strategy,

Tone
Positive 75/100
Event
Market update
Published
10 Jul 2026 02:10
Source
GlobeNewswire
Stock Titan Direct company coverage

Daré Bioscience CEO to discuss FloraSync launch, Q&A July 14

Daré Bioscience (NASDAQ: DARE) CEO Sabrina Martucci Johnson will participate in a Virtual Investor Closing Bell event on July 14, 2026, at 4:00 PM ET. She will provide a corporate overview, highlight the recent launch of FloraSync LF5™, discuss the company's growth strategy, and

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 12:14
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of Dare Bioscience, Inc. – NASDAQ:DARE

This article focuses on the "Price to sales forward" metric for Dare Bioscience, Inc. (NASDAQ: DARE). It appears to be a financial data page from TradingView, providing an overview of the company's financial performance. The content is primarily a navigation and site structure, w

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 04:10
Source
TradingView
Intellectia AI Direct company coverage

DARE Technical Analysis & Stock Price Forecast

This article provides a technical analysis and stock price forecast for Dare Bioscience Inc (DARE). Based on various technical indicators and moving averages, the consensus for DARE is currently a "Sell." Key support is identified at $1.969 and resistance at $2.199, with the stoc

Tone
Negative 28/100
Event
Guidance
Published
07 Jul 2026 12:41
Source
Intellectia AI
Contemporary OB/GYN Direct company coverage

Daré Bioscience launches prescription-free vaginal probiotic capsule for microbiome support

Daré Bioscience has launched Flora Sync LF5, a prescription-free vaginal probiotic capsule containing Limosilactobacillus fermentum LF5, available through its direct-to-consumer platform. Clinical trials showed comparable efficacy to miconazole in treating vulvovaginal candidiasi

Tone
Positive 70/100
Event
Market update
Published
06 Jul 2026 18:11
Source
Contemporary OB/GYN
TradingView Direct company coverage

Price to earnings forward of Dare Bioscience, Inc. – NASDAQ:DARE

The article focuses on the "Price to earnings forward" metric for Dare Bioscience, Inc. (NASDAQ: DARE) as presented on TradingView. It appears to be a financial data page rather than a detailed analytical article, showing the company's financial overview within the health technol

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 00:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Dare Bioscience, Inc. – NASDAQ:DARE

The article focuses on the enterprise value to EBIT forward for Dare Bioscience, Inc., traded on the Nasdaq Stock Market under the ticker DARE. It appears to be a financial data point provided by TradingView, possibly within a larger financial analysis platform. The content prima

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 20:39
Source
TradingView
Stock Titan Direct company coverage

Dare Bioscience (DARE) director receives 23,696 RSUs in lieu of cash pay

Dare Bioscience director Susan L. Kelley was granted 23,696 restricted stock units (RSUs) as compensation for her board service, replacing cash pay. Each RSU represents one share of common stock and will vest on January 4, 2027. Following this transaction, Kelley's direct holding

Tone
Neutral 50/100
Event
Balance sheet
Published
03 Jul 2026 00:10
Source
Stock Titan
Stock Titan Direct company coverage

Dare Bioscience (DARE) grants 38,862 RSUs to board director

Dare Bioscience (DARE) director William H. Rastetter has been granted 38,862 restricted stock units (RSUs) as compensation for his service on the board and its committees. These RSUs, granted at $0.00 per share, will vest on January 4, 2027, and directly increase his holdings to

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Dare Bioscience (DARE) director receives 26,540 RSUs in lieu of cash fees

Dare Bioscience director Robin Joan Steele was granted 26,540 restricted stock units (RSUs) as compensation for her board service, replacing cash fees. These RSUs, which represent a contingent right to one common stock share each, will vest on January 4, 2027. Following this tran

Tone
Neutral 50/100
Event
Balance sheet
Published
02 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Dare Bioscience (DARE) director awarded 30,805 RSUs as board compensation

Dare Bioscience director Gregory W. Matz received 30,805 restricted stock units (RSUs) as compensation for his service on the company's board and committees. These RSUs convert into one share each upon vesting on January 4, 2027, and after this grant, Matz directly holds 30,847 s

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Director Jessica Grossman gets 26,066 RSUs at Dare Bioscience (NASDAQ: DARE)

Jessica D. Grossman, a director at Dare Bioscience (NASDAQ: DARE), has been granted 26,066 Restricted Stock Units (RSUs) as non-cash compensation for her board service. These RSUs, valued at $0.00 per share for the grant, will fully vest on January 4, 2027, and each unit represen

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Daré Bioscience’s vaginal probiotic is now for sale online

Daré Bioscience (NASDAQ: DARE) has launched Flora Sync LF5™, a non-hormonal vaginal probiotic capsule, directly to consumers through its DARE Health Hub, marking its first consumer product revenue stream. The product, priced at $49 per box, is formulated with a vagina-specific pr

Tone
Positive 65/100
Event
Earnings
Published
01 Jul 2026 13:09
Source
Stock Titan
GlobeNewswire Direct company coverage

Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform

Daré Bioscience has launched Flora Sync LF5™, a vaginal probiotic capsule, making it available directly to consumers without a prescription. This launch signifies the company's transition into a revenue-generating entity, with Flora Sync LF5™ being its first consumer product. The

Tone
Positive 73/100
Event
Market update
Published
01 Jul 2026 08:55
Source
GlobeNewswire
TradingView Direct company coverage

Dare Bioscience, Inc. Actuals & Estimates (NASDAQ:DARE)

This article provides an overview of Dare Bioscience, Inc. (NASDAQ:DARE) stock, covering current price, market capitalization, volatility, and historical performance. It also includes analyst forecasts for future prices, details on recent actual earnings and revenue compared to e

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 05:40
Source
TradingView
TradingView Direct company coverage

DARE Forecast — Price Target — Prediction for 2027

This article provides a forecast for Dare Bioscience, Inc. (DARE) stock, including analyst price targets, historical performance, and key financial metrics. It highlights that three analysts have a 1-year price forecast, with a current DARE price of $2.09, and discusses the compa

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 20:40
Source
TradingView
GlobeNewswire Direct company coverage

Daré Bioscience Highlights Revenue Opportunity as CEO

Daré Bioscience announced its participation in a Virtual Investor "What This Means" segment, where CEO Sabrina Martucci Johnson discussed the upcoming commercial launch of Flora Sync LF5™. This vaginal probiotic capsule marks the company's first consumer health product, positioni

Tone
Positive 74/100
Event
Earnings
Published
25 Jun 2026 13:10
Source
GlobeNewswire
Stock Titan Direct company coverage

Daré Bioscience says Flora Sync LF5 could bring first product revenue

Daré Bioscience (NASDAQ: DARE) highlighted the upcoming June 2026 commercial launch of Flora Sync LF5™, a vagina-specific probiotic capsule intended to restore microbiome balance and support vaginal comfort. This product is Daré's first consumer health product and is anticipated

Tone
Positive 67/100
Event
Earnings
Published
25 Jun 2026 13:10
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 8K Dare Bioscience Inc For: 22 June By Investing.com

This article announces the filing of a Form 8K by Dare Bioscience Inc. on June 22. It mentions DARE's current stock performance and is primarily a notice about the regulatory filing rather than an in-depth analysis.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
22 Jun 2026 13:41
Source
Investing.com Canada
Stock Titan Direct company coverage

Dare Bioscience (DARE) unveils June 22, 2026 corporate investor presentation

Dare Bioscience (DARE) has released a new corporate investor presentation dated June 22, 2026, filed as Exhibit 99.1 under a Regulation FD disclosure. The presentation will be used for meetings with securities market participants and will be available on the company's website in

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 12:41
Source
Stock Titan
TradingKey Direct company coverage

Dare Bioscience Inc (DARE) Institutional Confidence

The institutional confidence score for Dare Bioscience Inc (DARE) is 3.00, placing it 94th in the Pharmaceuticals industry. Institutional shareholding has increased by 23.58% quarter-over-quarter, now standing at 8.57% of outstanding shares. James Simons is the largest institutio

Tone
Positive 66/100
Event
Market update
Published
18 Jun 2026 17:40
Source
TradingKey
TradingKey Direct company coverage

Dare Bioscience Inc (DARE) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Dare Bioscience Inc (DARE), listing major individual and institutional holders and their percentage of ownership. It also provides a breakdown of shareholder types, including corporations, investment advisors, and hedge funds. Fur

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 15:11
Source
TradingKey
GlobeNewswire Direct company coverage

Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026

Daré Bioscience, a health biotech company focused on women's health, announced that its President and CEO, Sabrina Martucci Johnson, will participate in multiple speaking engagements and deliver a corporate presentation at the BIO International Convention 2026. The convention off

Tone
Positive 74/100
Event
Market update
Published
18 Jun 2026 13:11
Source
GlobeNewswire